GLP-1 access guide
Are Ozempic and Wegovy the same drug?
Ozempic and Wegovy both contain semaglutide, but they are different branded finished products. Their approved indications, formulations and program terms are not identical. Current US sources identify injection and tablet products under both brands, so a brand-only comparison is incomplete. Sharing the ingredient does not authorize switching products or applying one brand’s coverage and savings rules to the other. [1][2][3]
At a glance
| Category | Ozempic | Wegovy | Sources |
|---|---|---|---|
| Ingredient | Semaglutide | Semaglutide | [1][3] |
| Brand organization | Novo Nordisk | Novo Nordisk | [1][3] |
| Current forms | Injection and tablets | Injection and tablets | [1][2][3] |
| Key label distinction | Diabetes-related indications; exact label varies by form | Weight-management and other specified indications; exact label varies by form | [1][2][3] |
The ingredient matches; the finished product still matters
Semaglutide is the ingredient name shown in both brands’ prescribing information. The brand and formulation identify the actual approved product. A directory can group them under an ingredient for research without treating the packages as identical. Confirm the full prescription description when comparing a provider’s offer or a pharmacy amount. A headline comparing Ozempic with Wegovy should preserve that distinction. [1][2][3]
This guide compares identity and approved labels rather than outcomes. It does not say which brand is better for a patient, provide dose conversions or infer that a reader should replace one product with the other. A clinician and pharmacist handle that individual question. The shared ingredient is a useful naming fact, not a directory-issued substitution instruction. [4][5]
Their approved indications differ
The Ozempic injection label includes type 2 diabetes and specified cardiovascular and kidney-risk indications in populations with type 2 diabetes. The Wegovy injection label includes weight reduction and maintenance, specified cardiovascular-risk reduction and a particular MASH indication. These are product-label categories, not a screening tool for a reader to determine eligibility. The full applicable label contains the exact conditions and population. [1][3]
Tablet indications also need the tablet label rather than an assumption drawn from the injection. Wegovy’s current label identifies tablet and injection indications separately, and FDA’s oral semaglutide label identifies Rybelsus and Ozempic tablets. Saying both brands contain semaglutide does not erase those differences. Ask the care team which product and label applies to the proposed prescription. [3][2]
Injection-only comparisons can be outdated
Wegovy’s current label includes tablets as well as injections. FDA’s 2026 naming approval also documents Ozempic tablets for the specified oral semaglutide formulation. A current comparison should therefore state the presentation it means. An older article focused on the injection products can remain valid history for that scope but should not be read as a complete current product inventory. [3][6]
A different form does not become equivalent simply because its number or brand is familiar. The labeling and preparation need their own identification. We do not provide instructions for translating an injection prescription into a tablet or for interpreting package quantities across products. Our oral-products guide explains the naming map; the clinician handles any proposed change in care. [2][3]
Savings offers apply to the named transaction
NovoCare publishes separate price and savings information for Wegovy and Ozempic. The branded package and qualifying offer need to match the prescription. A price for one presentation should not be applied to the other brand or to a compounded preparation under the shared ingredient heading. Introductory and continuing prices are also separate pieces of the offer. [7][8]
A telehealth service can add its own care fee or membership arrangement outside the pharmacy price. When researching access, keep the prescribing service and manufacturer pharmacy route distinct. The same ingredient name does not produce one universal all-in charge. The dedicated brand-cost guides give the current dated pharmacy figures, while provider profiles describe recorded clinical-service terms. [9][7][8]
Approval does not establish an individual coverage decision
A product having an FDA-approved indication is not the same as a particular insurer approving a pharmacy claim. Confirm the exact brand and formulation with the provider and plan before applying a coverage example. Manufacturer savings-card eligibility is another separate rule. The medication’s identity helps ask the right coverage question but does not settle a patient’s benefit or copayment. [4][7][8]
The directory’s state and medication-state pages also concern recorded provider access rather than personal coverage. A provider that can prescribe one of these products in a state should not be assumed to offer every presentation there. Ask the care organization and pharmacy about the actual proposed prescription after reviewing the source-backed options. [10]
Keep compounded semaglutide outside this brand pair
A compounded preparation described as semaglutide is a separate category from both approved brands. FDA says compounded and approved generic drugs are different. Marketing that compares the compound’s price with Wegovy or Ozempic does not make it either branded finished product. The full formulation and pharmacy identity should remain visible in a comparison. [11][5]
The useful comparison record is therefore brand, ingredient, form, applicable label and financial route. Those details explain how the two brands can share semaglutide without being identical. They also help distinguish a current tablet offer, a branded injection package and a compounded program when a telehealth site uses the short ingredient heading for several different services. [1][2][3][11]
Additional reading from a provider
These pages describe a provider’s perspective or its own service. The official documents cited in this guide establish regulatory, approval and program facts.
- Gentle Health: Ozempic, Wegovy, Zepbound and Mounjaro overview (provider-authored)
A provider-authored comparison of the named brands. The specific FDA-approved labels above establish this guide’s product and indication facts.
Checked
Sources
Sources are checked on the dates shown. Official documents establish product and program rules; provider sources describe their own offers and the additional reading identified above. Provider catalog examples retain their original price-check dates; this article’s preparation date does not refresh them.
- Novo Nordisk: Ozempic injection prescribing information — checked .
- FDA: Rybelsus and Ozempic tablet prescribing information — checked .
- FDA: Wegovy injection and tablet prescribing information, June 2026 — checked .
- FDA: development and approval process for drugs — checked .
- FDA: generic drug facts and approval requirements — checked .
- FDA: approval letter renaming Rybelsus formulation R2 as Ozempic tablets — checked .
- NovoCare: Wegovy cost and savings — checked .
- NovoCare Pharmacy: Ozempic self-pay terms — checked .
- FTC: trials, automatic renewals and subscriptions — checked .
- FDA BeSafeRx: online pharmacy questions — checked .
- FDA: compounding questions and answers — checked .
- Gentle Health: Ozempic, Wegovy, Zepbound and Mounjaro overview (provider-authored) — checked .